Skip to main content

Table 3 Comparison of BMI, HbA1c, FPG, Basal and Bolus Insulin Doses at Baseline and 26 weeks after IDeg Treatment by Gender

From: Real-world efficacy and safety of insulin degludec with mealtime rapid-acting insulin in type 1 diabetes in Indian pediatric population

Characteristics Baseline 26 weeks
BMI (kg/m2) (SDS)
 Female (n = 13) 17.73 ± 3.897 (0.07 ± 0.97) 18.07 ± 3.882(0.20 ± 0.82)
 Male (n = 17) 16.42 ± 2.885 (− 0.02 ± 0.93) 16.87 ± 2.099(0.16 ± 0.88)
HbA1c (%)
 Female (n = 13) 9.35 ± 1.824 8.37 ± 0.772*
 Male (n = 17) 9.88 ± 2.147 8.78 ± 2.074*
FPG (mg/dL)
 Female (n = 13) 157.77 ± 54.259 108.85 ± 25.980*
 Male (n = 17) 156.29 ± 32.330 109.76 ± 31.126*
Insulin dose (U/kg of body weight/day)
 Basal insulin
  Female (n = 13) 0.45 ± 0.115 0.49 ± 0.136
  Male (n = 17) 0.41 ± 0.148 0.44 ± 0.141*
 Bolus insulin
  Female (n = 13) 0.57 ± 0.212 0.43 ± 0.161*
  Male (n = 17) 0.44 ± 0.193 0.29 ± 0.122*
  1. BMI body mass index, FPG fasting plasma glucose, HbA1c glycated hemoglobin, SDS Standard Deviation Score
  2. *P < 0.05 versus baseline (paired t-test)
\